217 related articles for article (PubMed ID: 25137071)
21. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Huang L; Chen S; Yang W; Xu B; Huang T; Yang H; Zheng H; Wang Y; Song E; Zhang J; Cui S; Pang D; Tang L; Lei Y; Geng C; Shao Z
Oncotarget; 2015 Jul; 6(21):18683-92. PubMed ID: 26084292
[TBL] [Abstract][Full Text] [Related]
22. Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment.
Chekhun VF; Borikun TV; Bazas VМ; Andriiv AV; Klyusov OМ; Yalovenko TМ; Lukianova NY
Exp Oncol; 2020 Sep; 42(3):162-166. PubMed ID: 32996748
[TBL] [Abstract][Full Text] [Related]
23. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
24. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
[TBL] [Abstract][Full Text] [Related]
25. A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients.
Pal R; Choudhury T; Ghosh M; Vernakar M; Nath P; Nasare VD
Clin Transl Oncol; 2024 Jul; 26(7):1716-1724. PubMed ID: 38472557
[TBL] [Abstract][Full Text] [Related]
26. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
[TBL] [Abstract][Full Text] [Related]
27. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
[TBL] [Abstract][Full Text] [Related]
28. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.
Xue J; Chi Y; Chen Y; Huang S; Ye X; Niu J; Wang W; Pfeffer LM; Shao ZM; Wu ZH; Wu J
Oncogene; 2016 Jan; 35(4):448-58. PubMed ID: 25867061
[TBL] [Abstract][Full Text] [Related]
29. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
30. Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients.
Wang J; Chen S; Xu B; Yuan P; Ma F; Li Q; Zhang P; Cai R; Fan Y; Luo Y; Li Q
Thorac Cancer; 2017 May; 8(3):246-250. PubMed ID: 28402606
[TBL] [Abstract][Full Text] [Related]
31. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
32. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
Tumour Biol; 2013 Feb; 34(1):81-90. PubMed ID: 22983919
[TBL] [Abstract][Full Text] [Related]
33. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
[TBL] [Abstract][Full Text] [Related]
34. Serum microRNA-155 as a potential biomarker to track disease in breast cancer.
Sun Y; Wang M; Lin G; Sun S; Li X; Qi J; Li J
PLoS One; 2012; 7(10):e47003. PubMed ID: 23071695
[TBL] [Abstract][Full Text] [Related]
35. Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
Li Q; Liu M; Ma F; Luo Y; Cai R; Wang L; Xu N; Xu B
PLoS One; 2015; 10(8):e0136826. PubMed ID: 26305791
[No Abstract] [Full Text] [Related]
36. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
37. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A; Bachleitner-Hofmann T; Baumann S; Marchetti-Deschmann M; Rech-Weichselbraun I; Burghuber C; Pluschnig U; Bartsch R; Graf A; Greil R; Allmaier G; Steger G; Gnant M; Bergmann M; Oehler R
Br J Cancer; 2010 Oct; 103(8):1201-8. PubMed ID: 20877360
[TBL] [Abstract][Full Text] [Related]
38. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
Chen SC; Chang HK; Lin YC; Cheung YC; Tsai CS; Leung WM; Hsueh S; Chen MF
Onkologie; 2005 Jun; 28(6-7):339-44. PubMed ID: 15933422
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-143 is Associated With Pathological Complete Response and Regulates Multiple Signaling Proteins in Breast Cancer.
García-Vázquez R; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; Meneses-García A; Arce-Salinas C; Bargallo-Rocha E; Carlos-Reyes Á; López-González JS; Pérez-Plasencia C; Ramos-Payán R; Aguilar-Medina M; López-Camarillo C
Technol Cancer Res Treat; 2019 Jan; 18():1533033819827309. PubMed ID: 30755102
[TBL] [Abstract][Full Text] [Related]
40. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers.
Mar-Aguilar F; Mendoza-Ramírez JA; Malagón-Santiago I; Espino-Silva PK; Santuario-Facio SK; Ruiz-Flores P; Rodríguez-Padilla C; Reséndez-Pérez D
Dis Markers; 2013; 34(3):163-9. PubMed ID: 23334650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
